Stocks in the biotech industry are highly volatile and difficult to analyze.
Many biotech companies currently trading on the stock market have one or more drugs still completing the Food and Drug Administration (FDA) approval process. Drugs still in testing can have a big impact on a biotech company’s valuation.
Because there are many biotech companies that do not generate revenue, or their revenue is minimal, it is difficult to analyze these companies based on their fundamentals.
A simple screen based on current earnings, revenue, or any other financial figure would not show the whole value of a biotech company. Biotech stocks require a unique form of analysis, including:
Answering these questions will help you analyze the potential of a biotech company, and how the market is currently valuing it.
Using the DiscoverCI Stock Screener, we scan for biotech stocks on a daily basis..
The list is sorted by today’s volume, and includes the beta, marketcap, and last stock price.
We update this list daily. Last updated: June 20th, 2019
Stay up to date with our latest trade ideas, stock market news, tips and posts.
We respect your privacy and take protecting it seriously.
© 2018 DiscoverCI
Disclaimer: DiscoverCI LLC is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on DiscoverCI.com represent a recommendation to buy or sell a security. The information on this site, and in its related application software, spreadsheets, blog, email and newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. In no event shall DiscoverCI.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any product, content or other material published or available on DiscoverCI.com, or relating to the use of, or inability to use, DiscoverCI.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related blog, email and newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way.